MovDisordV3, PascalFrancis, Corpus, bibRecord, 000792

Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease

Identifieur interne : 000792 ( PascalFrancis/Corpus ); précédent : 000791; suivant : 000793

Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease

Auteurs : Claire L. Tomlinson ; Rebecca Stowe ; Smitaa Patel ; Caroline Rick ; Richard Gray ; Carl E. Clarke

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0512956

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Lévodopa, Traitement, Equivalent dose.

English descriptors

KwdEn :
- Dose equivalent, Levodopa, Nervous system diseases, Parkinson disease, Treatment.

Abstract

Interpretation of clinical trials comparing different drug regimens for Parkinson's disease (PD) is complicated by the different dose intensities used: higher doses of levodopa and, possibly, other drugs produce better symptomatic control but more late complications. To address this problem, conversion factors have been calculated for antiparkinsonian drugs that yield a total daily levodopa equivalent dose (LED). LED estimates vary, so we undertook a systematic review of studies reporting LEDs to provide standardized formulae. Electronic database and hand searching of references identified 56 primary reports of LED estimates. Data were extracted and the mean and modal LEDs calculated. This yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale. Using these conversion formulae to report LEDs would improve the consistency of reporting and assist the interpretation of clinical trials comparing different PD medications.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 15`
A08	`01`	`1`	`ENG`	`@1 Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease`
A11	`01`	`1`		`@1 TOMLINSON (Claire L.)`
A11	`02`	`1`		`@1 STOWE (Rebecca)`
A11	`03`	`1`		`@1 PATEL (Smitaa)`
A11	`04`	`1`		`@1 RICK (Caroline)`
A11	`05`	`1`		`@1 GRAY (Richard)`
A11	`06`	`1`		`@1 CLARKE (Carl E.)`
A14	`01`			`@1 Birmingham Clinical Trials Unit, University of Birmingham @2 Birmingham @3 GBR @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut.`
A14	`02`			`@1 Department of Neurology, Sandwell and West Birmingham Hospitals NHS Trust, City Hospital @2 Birmingham @3 GBR @Z 6 aut.`
A14	`03`			`@1 School of Clinical and Experimental Medicine, College of Medicine and Dental Sciences, University of Birmingham @2 Edgbaston, Birmingham @3 GBR @Z 6 aut.`
A20				`@1 2649-2653`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000191411680240`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 59 ref.`
A47	`01`	`1`		`@0 10-0512956`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Interpretation of clinical trials comparing different drug regimens for Parkinson's disease (PD) is complicated by the different dose intensities used: higher doses of levodopa and, possibly, other drugs produce better symptomatic control but more late complications. To address this problem, conversion factors have been calculated for antiparkinsonian drugs that yield a total daily levodopa equivalent dose (LED). LED estimates vary, so we undertook a systematic review of studies reporting LEDs to provide standardized formulae. Electronic database and hand searching of references identified 56 primary reports of LED estimates. Data were extracted and the mean and modal LEDs calculated. This yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale. Using these conversion formulae to report LEDs would improve the consistency of reporting and assist the interpretation of clinical trials comparing different PD medications.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 09`
C03	`03`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 09`
C03	`03`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 09`
C03	`04`	`X`	`FRE`	`@0 Traitement @5 10`
C03	`04`	`X`	`ENG`	`@0 Treatment @5 10`
C03	`04`	`X`	`SPA`	`@0 Tratamiento @5 10`
C03	`05`	`X`	`FRE`	`@0 Equivalent dose @5 11`
C03	`05`	`X`	`ENG`	`@0 Dose equivalent @5 11`
C03	`05`	`X`	`SPA`	`@0 Equivalente dosis @5 11`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 347`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0512956 INIST
ET :	Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease
AU :	TOMLINSON (Claire L.); STOWE (Rebecca); PATEL (Smitaa); RICK (Caroline); GRAY (Richard); CLARKE (Carl E.)
AF :	Birmingham Clinical Trials Unit, University of Birmingham/Birmingham/Royaume-Uni (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.); Department of Neurology, Sandwell and West Birmingham Hospitals NHS Trust, City Hospital/Birmingham/Royaume-Uni (6 aut.); School of Clinical and Experimental Medicine, College of Medicine and Dental Sciences, University of Birmingham/Edgbaston, Birmingham/Royaume-Uni (6 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 15; Pp. 2649-2653; Bibl. 59 ref.
LA :	Anglais
EA :	Interpretation of clinical trials comparing different drug regimens for Parkinson's disease (PD) is complicated by the different dose intensities used: higher doses of levodopa and, possibly, other drugs produce better symptomatic control but more late complications. To address this problem, conversion factors have been calculated for antiparkinsonian drugs that yield a total daily levodopa equivalent dose (LED). LED estimates vary, so we undertook a systematic review of studies reporting LEDs to provide standardized formulae. Electronic database and hand searching of references identified 56 primary reports of LED estimates. Data were extracted and the mean and modal LEDs calculated. This yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale. Using these conversion formulae to report LEDs would improve the consistency of reporting and assist the interpretation of clinical trials comparing different PD medications.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Pathologie du système nerveux; Lévodopa; Traitement; Equivalent dose
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Levodopa; Treatment; Dose equivalent
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; Levodopa; Tratamiento; Equivalente dosis
LO :	INIST-20953.354000191411680240
ID :	10-0512956

Links to Exploration step

Pascal:10-0512956

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease</title>
<author><name sortKey="Tomlinson, Claire L" sort="Tomlinson, Claire L" uniqKey="Tomlinson C" first="Claire L." last="Tomlinson">Claire L. Tomlinson</name>
<affiliation><inist:fA14 i1="01"><s1>Birmingham Clinical Trials Unit, University of Birmingham</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stowe, Rebecca" sort="Stowe, Rebecca" uniqKey="Stowe R" first="Rebecca" last="Stowe">Rebecca Stowe</name>
<affiliation><inist:fA14 i1="01"><s1>Birmingham Clinical Trials Unit, University of Birmingham</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
<affiliation><inist:fA14 i1="01"><s1>Birmingham Clinical Trials Unit, University of Birmingham</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rick, Caroline" sort="Rick, Caroline" uniqKey="Rick C" first="Caroline" last="Rick">Caroline Rick</name>
<affiliation><inist:fA14 i1="01"><s1>Birmingham Clinical Trials Unit, University of Birmingham</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gray, Richard" sort="Gray, Richard" uniqKey="Gray R" first="Richard" last="Gray">Richard Gray</name>
<affiliation><inist:fA14 i1="01"><s1>Birmingham Clinical Trials Unit, University of Birmingham</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Sandwell and West Birmingham Hospitals NHS Trust, City Hospital</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>School of Clinical and Experimental Medicine, College of Medicine and Dental Sciences, University of Birmingham</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0512956</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0512956 INIST</idno>
<idno type="RBID">Pascal:10-0512956</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000792</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease</title>
<author><name sortKey="Tomlinson, Claire L" sort="Tomlinson, Claire L" uniqKey="Tomlinson C" first="Claire L." last="Tomlinson">Claire L. Tomlinson</name>
<affiliation><inist:fA14 i1="01"><s1>Birmingham Clinical Trials Unit, University of Birmingham</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stowe, Rebecca" sort="Stowe, Rebecca" uniqKey="Stowe R" first="Rebecca" last="Stowe">Rebecca Stowe</name>
<affiliation><inist:fA14 i1="01"><s1>Birmingham Clinical Trials Unit, University of Birmingham</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
<affiliation><inist:fA14 i1="01"><s1>Birmingham Clinical Trials Unit, University of Birmingham</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rick, Caroline" sort="Rick, Caroline" uniqKey="Rick C" first="Caroline" last="Rick">Caroline Rick</name>
<affiliation><inist:fA14 i1="01"><s1>Birmingham Clinical Trials Unit, University of Birmingham</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gray, Richard" sort="Gray, Richard" uniqKey="Gray R" first="Richard" last="Gray">Richard Gray</name>
<affiliation><inist:fA14 i1="01"><s1>Birmingham Clinical Trials Unit, University of Birmingham</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Sandwell and West Birmingham Hospitals NHS Trust, City Hospital</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>School of Clinical and Experimental Medicine, College of Medicine and Dental Sciences, University of Birmingham</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dose equivalent</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Lévodopa</term>
<term>Traitement</term>
<term>Equivalent dose</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Interpretation of clinical trials comparing different drug regimens for Parkinson's disease (PD) is complicated by the different dose intensities used: higher doses of levodopa and, possibly, other drugs produce better symptomatic control but more late complications. To address this problem, conversion factors have been calculated for antiparkinsonian drugs that yield a total daily levodopa equivalent dose (LED). LED estimates vary, so we undertook a systematic review of studies reporting LEDs to provide standardized formulae. Electronic database and hand searching of references identified 56 primary reports of LED estimates. Data were extracted and the mean and modal LEDs calculated. This yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale. Using these conversion formulae to report LEDs would improve the consistency of reporting and assist the interpretation of clinical trials comparing different PD medications.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>15</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>TOMLINSON (Claire L.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>STOWE (Rebecca)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PATEL (Smitaa)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>RICK (Caroline)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GRAY (Richard)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CLARKE (Carl E.)</s1>
</fA11>
<fA14 i1="01"><s1>Birmingham Clinical Trials Unit, University of Birmingham</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Sandwell and West Birmingham Hospitals NHS Trust, City Hospital</s1>
<s2>Birmingham</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>School of Clinical and Experimental Medicine, College of Medicine and Dental Sciences, University of Birmingham</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>2649-2653</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000191411680240</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>59 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0512956</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Interpretation of clinical trials comparing different drug regimens for Parkinson's disease (PD) is complicated by the different dose intensities used: higher doses of levodopa and, possibly, other drugs produce better symptomatic control but more late complications. To address this problem, conversion factors have been calculated for antiparkinsonian drugs that yield a total daily levodopa equivalent dose (LED). LED estimates vary, so we undertook a systematic review of studies reporting LEDs to provide standardized formulae. Electronic database and hand searching of references identified 56 primary reports of LED estimates. Data were extracted and the mean and modal LEDs calculated. This yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale. Using these conversion formulae to report LEDs would improve the consistency of reporting and assist the interpretation of clinical trials comparing different PD medications.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Equivalent dose</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dose equivalent</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Equivalente dosis</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>347</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0512956 INIST</NO>
<ET>Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease</ET>
<AU>TOMLINSON (Claire L.); STOWE (Rebecca); PATEL (Smitaa); RICK (Caroline); GRAY (Richard); CLARKE (Carl E.)</AU>
<AF>Birmingham Clinical Trials Unit, University of Birmingham/Birmingham/Royaume-Uni (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.); Department of Neurology, Sandwell and West Birmingham Hospitals NHS Trust, City Hospital/Birmingham/Royaume-Uni (6 aut.); School of Clinical and Experimental Medicine, College of Medicine and Dental Sciences, University of Birmingham/Edgbaston, Birmingham/Royaume-Uni (6 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 15; Pp. 2649-2653; Bibl. 59 ref.</SO>
<LA>Anglais</LA>
<EA>Interpretation of clinical trials comparing different drug regimens for Parkinson's disease (PD) is complicated by the different dose intensities used: higher doses of levodopa and, possibly, other drugs produce better symptomatic control but more late complications. To address this problem, conversion factors have been calculated for antiparkinsonian drugs that yield a total daily levodopa equivalent dose (LED). LED estimates vary, so we undertook a systematic review of studies reporting LEDs to provide standardized formulae. Electronic database and hand searching of references identified 56 primary reports of LED estimates. Data were extracted and the mean and modal LEDs calculated. This yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale. Using these conversion formulae to report LEDs would improve the consistency of reporting and assist the interpretation of clinical trials comparing different PD medications.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; Lévodopa; Traitement; Equivalent dose</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Levodopa; Treatment; Dose equivalent</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Levodopa; Tratamiento; Equivalente dosis</SD>
<LO>INIST-20953.354000191411680240</LO>
<ID>10-0512956</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000792 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000792 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0512956
   |texte=   Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease

Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri